Nr (nicotinamide riboside)

Mechanism of action

After absorption, NR is converted primarily via nicotinamide riboside kinase (NRK1/NRK2) into nicotinamide mononucleotide (NMN), then into NAD+ via NMN adenylyltransferase (NMNAT). Increased NAD+ may modulate: (1) sirtuin activity (NAD+-dependent deacetylases) involved in metabolism and stress response; (2) PARP (poly-ADP-ribose polymerase) in DNA repair, with potential competition for NAD+; (3) CD38 (an NADase), which consumes NAD+ and increases with age in some contexts; (4) redox metabolism (NAD+/NADH) and mitochondrial function. In humans, the most consistent effect is the increase in NAD+ biomarkers in the blood compartment; effects on performance, insulin sensitivity, inflammation, or mitochondrial function are heterogeneous and depend on population, dose, and duration.

Supported benefits

• Increase in blood NAD+ biomarkers (e.g. NAD+ in PBMCs/whole blood, NAAD) in a dose-dependent manner (strong)
• Possible improvements in some cardiovascular markers (e.g. arterial stiffness/blood pressure in subgroups) in selected studies (limited)
• Effects on body composition, energy expenditure, or glucose metabolism in overweight/obese adults: mixed results, often null on primary endpoints (limited)
• Support for parameters of mitochondrial function or physical performance: evidence not consistent in humans (emerging)
• Reduction in some inflammatory/oxidative markers: variable and inconclusive results (emerging)

Safety & side effects

• Gastrointestinal disturbances (nausea, dyspepsia, diarrhea) reported in a minority of subjects
• Headache or fatigue (occasional reports)
• Possible changes in blood chemistry parameters in some studies (e.g. mild changes in liver enzymes or other markers), generally within clinically non-relevant ranges but worth monitoring in at-risk contexts
• Increase in nicotinamide methylation metabolites (e.g. MeNAM) as a biochemical consequence of increased NAD+ turnover; the long-term clinical significance is unclear

FAQ

Does NR really increase NAD+ in humans?

Yes: the evidence consistently shows dose-dependent increases in NAD+ biomarkers and related metabolites in the blood. This demonstrates a biochemical effect, not necessarily a clinical benefit.

Does increasing NAD+ mean “slowing aging”?

Not necessarily. Animal models suggest roles for NAD+ in age-related processes, but in humans there is a lack of robust evidence that NR improves hard clinical outcomes or slows aging in the medical sense.

Is NR different from niacin (nicotinic acid) and nicotinamide?

Yes. They are all forms of vitamin B3/NAD+ precursors, but they use partially different metabolic pathways and have different tolerability profiles (for example, niacin can cause flushing; NR generally does not).

Is NR better than NMN?

There is no definitive consensus. Both increase NAD+ metabolites; differences depend on pharmacokinetics, target tissues, and study quality. Head-to-head comparisons in humans are limited.

What are the most solid endpoints in NR studies?

The most solid endpoints are blood NAD+ biomarkers (NAD+, NAAD, and nicotinamide metabolites). Clinical endpoints (metabolic, cardiovascular, performance) are less consistent.

Are there signals of oncological risk?

NAD+ is involved in DNA repair and cellular metabolism, so there are theoretical considerations both pro- and anti-tumoral depending on the context. However, direct clinical data linking NR to cancer risk or tumor progression in humans are insufficient for conclusions.